Table 1.

Patient and procedural characteristics

CharacteristicIntention-to-TreatPer Protocolb
CoronaryPeripheral
Bicarbonate (n=195)Saline (n=196)P ValueBicarbonate (n=146)Saline (n=145)P ValueBicarbonate (n=35)Saline (n=42)P Value
Age (y)72±1072±90.7371±1172±90.3375±1074±90.41
Male sex (%)57581.00705854570.82
Weight (kg)89.1±19.788.3±22.30.7191.7±19.890.1±23.00.5180.3±18.082.1±19.90.70
CHF (%)32390.1431410.092938>0.99
Anemia (%)4545>0.9945480.724038>0.99
Diabetes (%)63550.1263570.2857520.82
Hypertension (%)94940.839594>0.9991980.32
PAD (%)3031>0.9915170.756967>0.99
Creatinine (mg/dl)1.98±0.621.85±0.490.022.01±0.621.86±0.510.031.93±0.511.84±0.460.45
eGFR (ml/min per 1.73 m2)31.7±7.733.8±7.30.0131.7±8.033.7±7.50.0331.2±7.233.2±6.70.23
CM volume (ml)110±66104±720.40109±67101±750.37112±62110±610.89
CM volume/eGFR3.46±2.703.05±2.190.123.57±3.023.01±2.330.083.51±1.913.43±2.000.86
Mehran risk scorea11.0±3.910.9±3.80.8011.0±3.911.3±3.70.5510.2±3.89.9±3.80.71
Use of NAC (%)48530.572424>0.9926310.80
Volume of IV fluid (ml/kg)12.54±3.7413.11±2.990.1013.00±2.4913.41±2.070.133.51±2.673.43±2.310.86
Hospital LOS (h)48530.5747540.5051520.95
  • Values are mean±SD or as otherwise indicated. The group undergoing coronary angiography comprised 74% of the patients enrolled. Their characteristics are shown separately from those undergoing peripheral arteriography. CHF, congestive heart failure; PAD, peripheral arterial disease; CM, contrast media; NAC, N-acetylcysteine; IV, intravenous; LOS, length of stay in hospital (hours).

  • a Arbitrary units reflecting low (≤5), moderate (6–10), high (11–15), and very high (≥16) risk for contrast-induced AKI (11).

  • b Per protocol excludes 23 patients who did not undergo contrast exposure and receive either treatment.